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SUMMARY
Neurological disorders caused by Cytomegalovirus (CMV) in patients with Acquired Immunodeficiency Syndrome (AIDS) are 
rarely reported in the Highly Active Antiretroviral Therapy (HAART) period. The objective of this study was to describe the main 
clinical and laboratory features of patients with CMV-related neurological complications in HIV-infected patients admitted to a referral 
center in São Paulo, Brazil. CMV disease requires the identification of the virus in the cerebrospinal fluid (CSF) using Polymerase 
Chain Reaction (PCR). Thirteen cases were identified between January, 2004 and December, 2008. The median age of patients was 
38 years and nine (69%) were men. At admission all patients were aware of their HIV status and only four (31%) patients were on 
HAART. Patients who were not on antiretroviral therapy before admission received HAART while inpatients. CMV disease was 
the first AIDS-defining illness in eight (62%) patients. The neurologic syndromes identified were diffuse encephalitis (n = 7; 62%), 
polyradiculopathy (n = 7; 54%), focal encephalitis (rhombencephalitis) (n = 1; 8%), and ventriculo-encephalitis (n = 1; 8%). Seven 
(54%) patients presented extra-neural CMV disease and four (31%) had retinitis. The median of CD4+ T-cell count was 13 cells/µL 
(range: 1-124 cells/µL). Overall in-hospital mortality was 38%. Eight patients used ganciclovir or foscarnet (in-hospital mortality: 
50%) and five patients used ganciclovir and foscarnet (in-hospital mortality: 20%). None of the patients fulfilled the diagnosis 
criteria of immune reconstitution inflammatory syndrome. Four patients were lost to follow-up, and three patients presented immune 
recovery and discontinued secondary prophylaxis. Although infrequent, distinct neurological syndromes caused by CMV continue to 
cause high mortality among AIDS patients. Survival depends upon the use of effective antiviral therapy against CMV and the early 
introduction of HAART.
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INTRODUCTION
Highly Active Antiretroviral Therapy (HAART) has decreased the 
morbidity and mortality rate in Human immunodeficiency virus (HIV) 
patients with complications caused by Cytomegalovirus (CMV)5,18. 
Reactivation of the infection in Acquired Immunodeficiency Syndrome 
(AIDS) patients usually presents itself as retinitis or gastrointestinal 
involvement, whereas other neurologic syndromes are considerably 
less common5. In this area, two Brazilian studies showed that these 
complications are rare in the HAART period28,33. However, neurologic 
complications caused by CMV continue to occur for several reasons: 
1) patients fail to use HAART, either because they are not in care or are 
non-adherent; 2) antiretroviral resistance; and 3) late HIV diagnosis (late 
presenters). Furthermore, the individual clinical impact of neurological 
disorders caused by CMV continues to be relevant. In this retrospective 
study, we report on a case series of HIV-infected patients with encephalitis, 
rhombencephalitis, ventriculoencephalitis, and/or polyradiculopathy 
secondary to CMV, and discuss diagnosis and therapeutic issues. 
PATIENTS AND METHODS
We performed a retrospective study between January, 2004 and 
December, 2008. All adult HIV-infected patients admitted to the Instituto 
de Infectologia Emílio Ribas, São Paulo, Brazil, with a neurological 
disorder caused by CMV were included. CMV disease required the 
identification of the virus in the cerebrospinal fluid (CSF) using 
Polymerase Chain Reaction (PCR). For this purpose, we reviewed the 
records of the Laboratory of Virology at the Instituto de Medicina Tropical 
de São Paulo, where the CSF-PCR for the diagnosis of CMV infection 
of the patients at our institution is performed. We reviewed the clinical 
charts of all patients. This study was approved by the Institutional Review 
Board of the Instituto de Infectologia Emilio Ribas. 
Clinical syndromes were defined as follows: 1) diffuse encephalitis: 
progressive encephalopathy or dementia syndrome; 2) focal encephalitis 
(rhombencephalitis): focal signs indicative of brainstem and/or cerebella 
involvement; 3) ventriculo-encephalitis: lethargy or mental confusion, 
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nystagmus, and unilateral or bilateral cranial nerve palsies; and 4) 
polyradiculopathy: progressive ascending bilateral weakness, distal 
sensory loss, arreflexia, and bladder and/or anal sphincter dysfunction. 
These definitions were adapted from studies published elsewhere17,27,29.
The CMV DNA amplification was performed using a standard 
PCR technique that amplified the gB gene, according with CHOU 
& DENNISON6. HIV infection was documented by HIV-1 antibody 
enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. 
Median was compared using Wilcoxon rank sum test with continuity 
correction. 
RESULTS
A total of 13 HIV-infected patients with neurological complications 
secondary to CMV were included. All cases with positive CSF PCR 
for CMV DNA presented clinical manifestation compatible with CMV 
disease (no false positive cases were identified). Table 1 shows the main 
clinical and laboratory features of our patients. Nine (69%) were men and 
median age was 38 years (range: 28-58 years). All patients were aware 
of their HIV status before the admission. The median diagnosis of HIV 
infection was 36 months (range: 1-216 months). In eight (62%) patients, 
CMV disease was the first AIDS-defining illness. None of the patients 
presented histories of CMV disease but all of them had documented 
history of CMV infection with antibody detection (CMV IgG). Four 
(31%) patients were on HAART at admission: two had extensive 
multidrug resistance and two reported irregular treatment. The clinical 
syndromes identified were: encephalitis (n = 7, 54%), polyradiculopathy 
(n = 7, 54%), focal encephalitis (rhombencephalitis) (n = 1, 8%), and 
ventriculo-encephalitis (n = 1, 8%). Three (23%) patients presented 
polyradiculopathy and encephalitis simultaneously. Seven (54%) patients 
presented extra-neural CMV disease, including four (31%) with retinitis, 
although ophthalmoscopic examination was performed in all cases. 
In only one case the diagnosis of CMV neurologic complication was 
considered in the emergency room of our institution.
The median of CD4+ T-cell count was 13 cells/µL (range: 1-124 cells/
µL).  In CSF, the total leukocyte count median was 3 cells/mm3 (range: 
1-3150 cells/mm3), glucose median was 50 mg/dL (range: 10-89 mg/
dL), and protein median was 113 mg/dL (range:25-914 mg/dL). Normal 
CSF was observed in only one case. The quantitative pp65 antigenemia 
assay median was 10 positive cells per 400,000 neutrophils (range: 0-96 
positive cells per 400,000 neuthophils). 
Brain computed tomography (CT) imaging showed hypodense bi-
frontal areas in the white matter of cases 7,9,10. Magnetic resonance 
imaging (MRI) was performed in four patients: cases 9 and 10 showed 
hyperintense bi-frontal areas on T2-weighted and fluid attenuated 
inversion recovery images (FLAIR), confirming the CT findings; 
Table 1 
Main clinical and laboratory characteristics of 13 HIV-infected patients with neurologic Cytomegalovirus complications
Case Age/Sex AIDS-defining  
condition
Clinical syndrome Extra-neural 
CMV disease
CD4+ cell/mL pp65 antigen Treatment In-hospital 
outcome
1 36 / M Toxoplasmosis Polyradiculopathy Not 2 56 cells Ganciclovir + 
Foscarnet
Alive
2 41/ M Toxoplasmosis Polyradiculopathy Not 46 72 cells Ganciclovir Death
3 30 / M Neurologic CMV Polyradiculopathy Colitis 54 NA Ganciclovir Death
4 29 / M Neurologic CMV Diffuse encephalitis + 
Polyradiculopathy
Not 124 96 cells Ganciclovir + 
Foscarnet
Alive
5 29 / M Neurologic CMV Encephalitis + 
Polyradiculopathy
Not 2 NA Ganciclovir Death
6 38 / F Neurologic CMV Diffuse encephalitis Not 37 NA Ganciclovir Alive
7 58 / F Neurologic CMV Diffuse encephalitis Not 14 Negative Ganciclovir Alive
8 44 / F Neurologic CMV Ventrículo-encephalitis Retinitis 13 NA Ganciclovir + 
Foscarnet
Alive
9 45 / M Toxoplasmosis Diffuse encephalitis Retinitis, 
Esophagitis
1 NA Ganciclovir Death
10 58 / M Neurologic CMV Diffuse encephalitis Retinitis 9 Negative Ganciclovir Alive
11 53 / F Wasting 
syndrome
Diffuse encephalitis + 
Polyradiculopathy
Pneumonitis 12 11 cells Foscarnet Alive
12 28 / M Neurologic CMV Myeloradiculopathy Gastric ulcer 14 9 cells Ganciclovir + 
Foscarnet
Alive
13 34 / M Toxoplasmosis Focal encephalitis 
(Rhombencephalitis)
Retinitis 12 Negative Ganciclovir + 
Foscarnet
Death
M = male; F = female; NA = not available
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case 8 showed hyperintense periventricular areas on T2-weighted 
images, FLAIR and enhancement in this topography after gadolinium 
administration; and the case 13 showed one hyperintense image on T2-
weighted and FLAIR in the brainstem. 
Median time of hospitalization was 60 days (range: 13-111 days). 
Median time to anti-Cytomegalovirus treatment was 28 (range: 6-60) 
days. Median use time of these drugs was 28 (range: 6-56) days and 
30 (range: 16-60) days in patients with monotherapy and combination 
therapy, respectively. Five (63%) of eight patients that used ganciclovir 
or foscarnet died and one (20%) of five patients that used ganciclovir plus 
foscarnet died. However, this difference was not significant (p = 0.56). 
The decision to use combination therapy considered the hematological 
and renal function of the patients and the neurologic status. Thus, the 
patients with more severe disease received ganciclovir and foscarnet. 
After reviewing the history of treatment, all patients were on HAART 
within the first two weeks of admission. The two patients with triple-class 
resistance received a non-suppressive regimen. 
Overall in-hospital mortality was 38% (5/13): three as a result 
of nosocomial pneumonia and two secondary to CMV encephalitis. 
Autopsy was not performed in any case. One patient died due to acute 
renal failure after six months of discharge, when he has been receiving 
maintenance therapy with foscarnet and taking tenofovir, lamivudine, 
and efavirenz (CD4 = 326 cells/µL; VL < 50 copies/mL). None of 
the patients fulfilled the diagnosis criteria of immune reconstitution 
inflammatory syndrome (IRIS)32. Nevertheless, this complication could 
not be completely overlooked in all cases. One year after discharge, 
four patients had at least one outpatient evaluation and three were lost 
to follow-up. Among the three patients available one year after the 
diagnosis, two received ganciclovir plus foscarnet in the induction phase 
and the other one received ganciclovir. However, all these three patients 
received secondary prophylaxis with ganciclovir. The CD4+ T-cell count 
median of the three available patients was 189 cells/µL (range: 180-214 
cells/µL), all presented HIV-1 viral < 50 copies/mL, and adequate use 
of HAART. In all cases, CMV therapy was discontinued after CD4+ T 
cell count exceeded 100 cells/µL for six months.
Table 2 shows times from admission to diagnosis, admission to death, 
and diagnosis to death of our patients. The median time from admission 
to death was 68 days (range: 8-57 days). The median time from correct 
diagnosis to death was 44 days (range: 6-104 days). The median times 
from admission to diagnosis was 9.5 days (range: 5-25 days) among 
survivals and 23 days (range: 8-57 days) among deaths (p = 0.09). 
DISCUSSION
We found that neurologic CMV complications, although uncommon, 
continue to cause important mortality in our setting. Of note, all patients 
were aware of their HIV infection status and most patients presented 
CMV disease as initial AIDS defining illness. A subset of patients 
obtained clinical and laboratory improvement and were alive one year 
after the diagnosis of neurologic CMV complication. 
Retinitis is the most common manifestation of CMV infection in 
patients with AIDS and its diagnosis is usually clinical. However, the 
spectrum of neurologic CMV complications is broad and their diagnosis 
and treatment is more challenging. In the present study, similar to some 
reports of the pre HAART period2,26, approximately 30% of patients with 
neurologic CMV complications presented concomitant CMV retinitis. 
For this reason, routine ophthalmologic evaluation should be performed 
in all these patients. However, most patients will have simultaneous 
involvement of other organs at autopsy11.
Clinical studies performed in developed countries in the HAART era 
reported a prevalence of CMV encephalitis < 2%21. Similar figures have 
been reported in hospital-based studies in Brazil28,33. 
As in the pre-HAART period, all patients included in this study 
presented with very low CD4+ T cell counts. Most (~ 70%) had not been 
using HAART. This picture reflects failures in HIV therapy, particularly 
in Brazil, a developing country with a universal and free access anti-
retroviral program. It is important to reinforce that these serious 
neurologic CMV complications are best prevented by using HAART to 
maintain the CD4+ T cell counts > 100 cells/µL5.
Neurologic CMV complication was the first AIDS-defining condition 
in ~ 60% of our patients. Conversely, this figure was only ~ 10% in 
the pre HAART period2,26. This finding suggests that CMV should be 
included in the differential diagnosis of neurologic complaints in AIDS 
patients with severe immunosuppression, and without history of previous 
AIDS-defining conditions. 
Presumptive clinical diagnosis of some neurologic CMV syndromes 
can be made on the basis of a combination of signs and symptoms, 
imaging, and CSF findings24,25. Distinct clinical syndromes such as 
ventriculo-encephalitis and polyradiculopathy were well described 
in classical studies of the pre HAART period. However, neurologic 
Table 2 
Times from admission to diagnosis, admission to death, and diagnosis to death 
in 13 HIV-infected patients with neurologic cytomegalovirus complications
Case Time from 
admission 
to diagnosis 
(days)
Time from 
admission 
to death 
(days)
Time from 
diagnosis
 to death 
(days)
1 5 Alive Alive
2 14 118 104
3 23 68 45
4 11 Alive Alive
5 57 101 44
6 25 Alive Alive
7 15 Alive Alive
8 9 Alive Alive
9 8 14 6
10 10 Alive Alive
11 7 Alive Alive
12 7 Alive Alive
13 28 37 9
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complications due to CMV are not usually considered in the emergency 
room, as was observed in the present study. In contrast, CMV encephalitis 
may be difficult to differentiate from those of HIV encephalitis. 
A neuropathology study of HIV-infected patients reported 28 (17%) 
cases of CMV encephalitis, most of them with pre-mortem diagnosis of 
HIV dementia, showing that CMV has been underestimated as a cause 
of neurocognitve disorders15. Our results reinforce the importance of in 
vivo diagnosis of CMV encephalitis and the need to include this etiology 
in the differential diagnosis of patients with clinical suspicion of HIV 
dementia and severe immunosuppression. On the other hand, encephalitis 
has been described even in patients already receiving ganciclovir23.
CMV polyradiculopathy causes a Guillain-Barré-like syndrome 
characterized by urinary retention and progressive bilateral leg weakness. 
The differential diagnosis in HIV-infected patients includes other 
opportunistic infections (tuberculosis, herpes simplex virus - HSV - type 
2, varicella-zoster virus, and toxoplasmosis), syphilis, and lymphoma26.
Rhombencephalitis is an unusual manifestation of CMV disease 
and when isolated its diagnosis is more difficult. Their main differential 
diagnosis includes HSV-1, tuberculosis and lymphoma27.
Neurologic CMV complications usually occur in patients with very 
low CD4 cell counts (< 50 cells/µL) and are often simultaneously present 
at other sites (retina, gastrointestinal tracts, blood, etc)20. However, 
6/13 patients of the present series did not present extra-neural CMV 
diseases, except by the presence of pp65 antigenemia in three of them. 
Antigenemia was not performed in five patients; of those, two had 
retinitis, one had colitis and the other two had not any extra-neurologic 
disease. The presence of CMV viremia is an important factor but it is 
not required in the setting of “compartmentalized infections” such as 
colitis, esophagitis or neurologic disease. The determination of pp65 
antigenemia depends on a technician and the absence of antigenemia is 
not equal to the absence of viremia, since CMV-PCR in blood samples 
is a more sensitive method. CMV complications restricted to the nervous 
system should be considered in the adequate clinical and immunological 
context. In this setting, minimally invasive diagnosis using CSF-PCR for 
CMV DNA is particularly useful. This tool showed 62-100% sensitivity 
and 89-100% of specificity in CMV encephalitis and polyradiculopathy29, 
and present positive and negative predictive values ranged between 86-
95% and 95-98%, respectively7-9. 
Although neurologic CMV complications are unusual, it is likely 
that they are under-diagnosed or -reported in developing countries 
because of difficult access to reference centers with diagnostic support, 
including molecular diagnosis and neuroimaging. The results of the 
present study suggest that CMV might be more frequently diagnosed 
when appropriate diagnostic procedures can be employed. Furthermore, a 
timely diagnosis and prompt treatment is critical for an adequate clinical 
response. However, the absence of specific treatment in most low- and 
middle-income countries constitutes an unsolved problem that limits the 
outcome for these patients.
Examination of CSF is non-specific for the diagnosis of CMV 
encephalitis due to their variable profile. CMV encephalitis rarely 
causes pleocytosis; if a pleocytosis occurs it is usually low grade and 
consists predominantly of lymphocytes and monocytes. On the other 
hand, CSF abnormalities in patients with CMV polyradiculopathy can 
mimic the pattern of acute bacterial meningitis, including a pleocytosis 
with polymorphonuclear leucocyte preponderance, a raised protein 
concentration and hypoglycorrhachia or a reduced CSF:plasma 
glucose ratio24,25. Some studies reported 50-76% of patients with CMV 
poliradiculopathy and “typical” polymorphonuclear preponderant 
pleocytosis21. In our study we confirm a broad spectrum of CSF patterns 
in CMV polyradiculopathy.
In the pre HAART period, the overall prognosis of neurologic CMV 
complications was poor, independent of treatment, with survival of one 
to four months2,3,11,26. For example, in a retrospective study of 103 cases 
published with CMV polyradiculopathy, the mean survival time for 
untreated and treated patients with ganciclovir was 5.4 and 14.6 weeks, 
respectively1. In contrast, in the present study, the use of HAART along 
with the specific treatment for CMV resulted in an effective immune 
recovery that improved the outcome of a subset of patients. 
Both ganciclovir and foscarnet are known to penetrate well in to the 
CSF. For example, there are reports that CSF ganciclovir concentrations 
were 24-67% of the concurrent plasma concentrations and foscarnet was 
reported to distribute to the CSF in a concentration varying from 13 to 
68% of the concomitant plasma concentration18. There is no data about 
cidofovir CSF concentrations as a percentage of plasma concentration. 
Nevertheless, cidofovir CSF penetration is low12.
The efficacies and toxicities of approved treatments for CMV retinitis 
have been established by randomized prospective trials. In contrast, 
there have been no prospective randomized trials of treatment for CMV 
neurologic disease5. The largest series published was an open non-
comparative multicentre study of 31 patients with CMV encephalitis of 
myelitis, 60% of them with previous CMV2. This study was performed 
in the pre HAART period, and all patients received ganciclovir plus 
foscarnet by a media of six weeks. Approximately 75% of patients 
presented clinical improvement or stabilization and 32% of patients 
discontinued one of the two drugs because of side-effects. The median 
survival time was only three months. 
Treatment recommendations to neurologic CMV complications 
are diverse, but most suggest ganciclovir, foscarnet or both agents in 
combination9,13,14,17,19,27,29,34 and highlight that initiating therapy promptly 
is critical for an optimal clinical response. Some authors recommend 
combination therapy in all cases11,20 or in patients who have received prior 
antiviral therapy for CMV or in patients with disease progression under 
monotherapy22,34. In the present study we observed that most patients with 
combination therapy were discharged alive, but it was not significantly 
higher compared with those receiving monotherapy. Nevertheless, the 
choice between one or two anti-CMV drugs was arbitrary, but usually 
combination treatment was indicated in patients with more severe 
neurologic disease. 
Although there is few data that support the use of cidofovir in the 
treatment of CMV-related neurological disorders31, its use could be 
considered in those failing or intolerant of ganciclovir and foscarnet 
therapy.
The duration of induction treatment is variable in the literature (3-8 
weeks)11,27,29. We prefer at least four weeks, but in some cases a response 
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will be noted after this period. A close clinical follow up and CSF-PCR for 
CMV DNA can guide the optimal duration of treatment on an individual 
basis. However, the retrospective nature of our study and the small number 
of cases evaluated precludes any definitive recommendation about the 
optimal treatment of neurologic CMV complications in AIDS patients.
Maintenance therapy options include one (valganciclovir, ganciclovir 
or foscarnet) or two drugs (valganciclovir or ganciclovir plus foscarnet). 
Maintenance monotherapy seems to be particularly advisable in patients 
without previous use of ganciclovir where the possibility to obtain an 
adequate immune reconstitution due to HAART is a realistic one. Although 
may not be readily available in most developing countries and most data 
was extrapolated from Cytomegalovirus retinitis, the use of valganciclovir 
(an orally administered prodrug of ganciclovir) seem to be the preferred 
regimen to maintenance4. The use of maintenance therapy with foscarnet 
is feasible but cumbersome since it requires a permanent line for its 
administration and frequent monitoring of electrolytes and kidney function. 
Although the optimal time to discontinue maintenance therapy is unknown, 
some authors suggest that can be safely discontinued in patients with 
inactive disease and sustained immune reconstitution (CD4+ T cells count 
> 100 cells/mL for 3-6 months on HAART)17,20,22. Three of our patients 
discontinued maintenance therapy after six months with CD4+T cell count 
> 100 cells/mL. Recommended therapy regimens are shown in Table 3.
In contrast to cytomegalovirus immune recovery uveitis4, IRIS seems 
to be very rare in patients with neurologic cytomegalovirus complications. 
In accordance with this, none of the included patients in this study fulfilled 
the diagnosis criteria of IRIS32.
In conclusion, neurologic CMV complications are uncommon but 
distinct diseases and continue to cause high mortality in our setting. 
CSF-PCR for detection of CMV DNA permits a timely diagnosis. 
Although there is no a definitive choice treatment, the use of specific 
antivirals associated to HAART improved the outcome of a subset of 
patients. 
RESUMO
Complicações neurológicas causadas pelo Citomegalovírus em 
pacientes com aids: estudo retrospectivo de 13 casos e revisão da 
literatura 
As complicações neurológicas causadas pelo Citomegalovírus 
(CMV) em pacientes com aids são raramente relatadas na era HAART. 
O objetivo deste estudo foi descrever as principais características clínicas 
e laboratoriais de pacientes com complicações neurológicas associadas 
ao CMV em pacientes com aids admitidos em centro de referência em 
Sao Paulo, Brasil. A doença citomegálica precisou da identificação 
do vírus no líquor mediante a reação em cadeia da polimerase (PCR). 
Treze casos foram identificados entre janeiro de 2004 e dezembro de 
2008. A mediana da idade foi 38 anos e nove (69%) eram homens. 
Na admissão, todos os pacientes sabiam do seu status sorológico para 
o HIV e apenas quatro (31%) pacientes usavam HAART. A doença 
citomegálica foi a primeira doença definidora de aids em oito (62%) 
pacientes. As síndromes neurológicas identificadas foram: encefalite 
difusa (n = 7; 62%), polirradiculopatia (n = 7; 54%), encefalite focal 
(romboencefalite) (n = 1; 8%), e ventrículo-encefalite (n = 1; 8%). Sete 
(54%) pacientes apresentaram doença citomegálica fora do sistema 
nervoso e quatro (31%) tiveram retinite. A mediana da contagem de 
células CD4+ foi 13 células/µL. A mortalidade global durante a internação 
foi 38%. Oito pacientes usaram ganciclovir ou foscarnet (mortalidade: 
50%) e cinco pacientes usaram ganciclovir e foscarnet (mortalidade: 
20%). Nenhum paciente apresentou critérios diagnósticos da síndrome 
inflamatória de reconstituição imunológica. Quatro pacientes foram 
perdidos do acompanhamento ambulatorial e três pacientes apresentaram 
reconstituição imunológica e descontinuaram as profilaxias secundárias. 
Embora raras, as particulares síndromes neurológicas causadas pelo 
CMV continuam causando elevada mortalidade em pacientes com aids. 
A sobrevida depende do uso de terapia antiviral efetiva contra o CMV e 
a introdução oportuna do HAART.
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